Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $7.50

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been given a consensus rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $7.50.

GANX has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and issued a $5.00 price objective on shares of Gain Therapeutics in a research note on Tuesday, June 30th. Roth Capital reiterated a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, July 1st.

Institutional Investors Weigh In On Gain Therapeutics

Large investors have recently bought and sold shares of the stock. Sprott Inc. bought a new stake in Gain Therapeutics in the fourth quarter valued at $39,000. Commonwealth Equity Services LLC acquired a new stake in shares of Gain Therapeutics in the 4th quarter valued at about $41,000. Millennium Management LLC bought a new stake in Gain Therapeutics in the 4th quarter valued at about $45,000. JPMorgan Chase & Co. acquired a new position in Gain Therapeutics during the 3rd quarter worth approximately $47,000. Finally, Engineers Gate Manager LP acquired a new position in Gain Therapeutics during the 4th quarter worth approximately $47,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $1.82 on Tuesday. The company has a market capitalization of $77.62 million, a PE ratio of -3.14 and a beta of 0.15. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34. The firm has a fifty day simple moving average of $1.79 and a 200 day simple moving average of $1.97.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). During the same quarter in the prior year, the firm posted ($0.16) EPS. On average, sell-side analysts forecast that Gain Therapeutics will post -0.54 EPS for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.